Telmisartan as a metabolic sartan: The first meta-analysis of randomized controlled trials in metabolic syndrome

Telmisartan has been proposed to be a promising cardiometabolic sartan due to its unique peroxisome proliferator-activated receptor-gamma-inducing property. To determine whether telmisartan improves metabolic parameters in metabolic syndrome, we perform the first meta-analysis of randomized controlled trials (RCTs). MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched through September 2012 using PubMed and OVID. Eligible studies were RCTs of telmisartan therapy enrolling individuals with metabolic syndrome and reporting metabolic parameters as outcomes. Of 31 potentially relevant articles screened initially, 10 reports of RCTs, enrolling a total of 546 patients with metabolic syndrome, were identified and included. Pooled analysis suggested significant reductions in % changes of fasting glucose (standardized mean difference, −0.51; 95% confidence interval [CI], −0.96 to −0.06; P = .03), insulin (−0.23; 95% CI, −0.40 to −0.06; P = .008), glycosylated hemoglobin (−0.26; 95% CI, −0.44 to −0.08; P = .005), and homeostasis model assessment index (−0.22; 95% CI −0.39 to −0.05; P = .01); and a significant increase in % changes of adiponectin (0.75; 95% CI, 0.40 to 1.09; P < .0001) among patients with metabolic syndrome randomized to telmisartan versus control therapy. Telmisartan therapy appears to significantly improve metabolic parameters in patients with metabolic syndrome.